Harry H. Yoon, MD

Articles

A Look Towards the Future of ESCC

February 6th 2023

Closing out their conversation, Drs Saba and Yoon share their hopes for the future of ESCC, including elucidating the molecular mechanisms behind immune evasion and treatment response to chemotherapy, radiation, and immunotherapy.

Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell Cancers

January 30th 2023

A review of other ongoing trials and emerging treatment regimens in the space and a summary of takeaways from trials on other squamous cell cancers that may also be applied to ESCC.

The Potential Impact of Tislelizumab on First-Line ESCC Treatment

January 30th 2023

Drs Saba and Yoon reflect on how the potential FDA approval and availability of tislelizumab might change first-line ESCC treatment paradigms in the future.

RATIONALE-306 Data on Tislelizumab in ESCC

January 25th 2023

Dr Yoon introduces tislelizumab, an anti-PD-1 immunotherapy regimen being investigated as a first-line ESCC treatment option in combination with chemotherapy, and discusses recent conference data from the RATIONALE-306 trial.

Insights on ESCC First-Line Treatment Selection

January 25th 2023

Drs Saba and Yoon share the factors they consider when choosing among available first-line regimens for ESCC, including clinical trial data and the patient’s PD-L1 expression status.

First-Line Options for Advanced/Metastatic Disease

January 16th 2023

A focused discussion on the available first-line treatment options for advanced/metastatic ESCC.

The Impact of Biomarker Results on Prognosis and Treatment Decision-Making

January 16th 2023

Drs Saba and Yoon share how a patient’s biomarker testing results typically affect prognosis and how they may influence subsequent treatment decision-making.

Approaches to Biomarker Testing for ESCC

December 21st 2022

Expert perspectives on the process of biomarker testing, including PD-L1 testing, for patients with unresectable locally advanced or metastatic ESCC.

Trends in ESCC Incidence and Observations from Clinical Practice

December 21st 2022

Nabil Saba, MD, FACP and Harry Yoon, MD, briefly review the incidence of esophageal squamous cell carcinoma (ESCC), and describe how many patients present with unresectable locally advanced or metastatic disease in their clinical practice.

Dr. Yoon on Updated Data on Tislelizumab Plus Chemotherapy in ESCC

June 30th 2022

Harry H. Yoon, MD, discusses updated findings from the phase 3 RATIONALE-306 trial in esophageal squamous cell carcinoma.

Dr. Yoon on Updated Results of the KEYNOTE-061 Study in Advanced Gastric/GEJ Cancer

July 2nd 2020

Harry H. Yoon, MD, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.

Dr. Yoon on Immunotherapy in Gastric Cancer

September 25th 2017

Harry H. Yoon, MD, associate professor of oncology, Mayo Clinic, discusses the benefits demonstrated with nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with gastric cancer.